Effects of streptococcal preparation OK-432 on cytokine induction in spleen and tumour tissues of mice bearing MH-134 tumour cells

Journal of International Medical Research

Volumn 27, Issue 1, 1999, Pages 27-37

  Nakatani, S ^a   Iwagaki, H ^a   Okabayashi, T ^a   Matsubara, N ^a   Isozaki, H ^a   Takakura, N ^a   Horimi, T ^a   Tanaka, N ^a  

^a OKAYAMA UNIVERSITY MEDICAL SCHOOL   (Japan)

Author keywords

Antitumour immunity; Cytokine mRNA; Cytokines; OK 432; Reverse transcriptase polymerase chain reaction

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 1BETA; INTERLEUKIN 6; MESSENGER RNA; PICIBANIL; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; CYTOKINE PRODUCTION; IMMUNITY; INTRATUMORAL DRUG ADMINISTRATION; MALE; MOUSE; NONHUMAN; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPLEEN; SUBCUTANEOUS DRUG ADMINISTRATION; TUMOR; TUMOR CELL;

EID: 0033029350     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/030006059902700104     Document Type: Article

References (35)

1. Talmadge JE, Herberman RB: The preclinical screening laboratory: evaluation of immunomodulatory and therapeutic properties of biological response modifiers. Cancer Treat Res 1986; 70: 171-182.
2. Watanabe Y, Iwa T: Clinical value of immunotherapy for lung cancer by the streptococcal preparation OK-432. Cancer 1987; 6: 169-180.
3. Mukai M, Kubota S, Morit S, et al: A pilot study of combination therapy of radiation and local administration of OK-432 for esophageal cancer. Cancer 1995; 75: 2276-2280.
4. Tanaka N, Gouchi A, Ohara T, et al: Intratumoral injection of a streptococcal preparation, OK-432, before surgery for gastric cancer. Cancer 1994; 74: 3097-3103.
5. Maehara Y, Okuyama T, Kakeji Y, et al: Postoperative immunochemotherapy including streptococcal lysate OK-432 is effective for patients with gastric cancer and serosal invasion. Am J Surg 1994; 168: 36-40.
6. Fukui H, Koishihara Y, Nagamuta M, et al: Production of interleukin 6 by human spleen cells stimulated with streptococcal preparation OK-432. Immunol Lett 1989; 21: 127-130.
7. Ichimura O, Suzuki S, Saito M, et al: Augmentation of interleukin 1 and interleukin 2 production by OK-432. Int J Immunopharmacol 1985; 7: 263-270.
8. Oshimi K, Kano S, Takaku F, et al: Augmentation of mouse natural killer cell activity by a streptococcal preparation, OK-432. J Natl Cancer Inst 1980; 65: 1265-1269.
9. Saito M, Ebina T, Koi M, et al: Induction of interferon gamma in mouse spleen cells by OK-432, a preparation of Streptococcus pyogenes. Cell Immunol 1982; 68: 187-192.
10. Misaki T, Watanabe Y, Iida Y, et al: Recruitment of T lymphocytes and induction of tumor necrosis factor in thyroid cancer by a local immunotherapy. Cancer Immunol Immunother 1992; 35: 92-96.
11. Yamaue H, Tanimura H, Iwahashi M, et al: Role of interleukin-2 and interferon-γ in induction of activated natural killer cells from mice primed in vivo and subsequently challenged in vitro with the streptococcal preparation OK-432. Cancer Immunol Immunother 1989; 29: 79-86.
12. Chomczynski P, Sacchi N: A new method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987; 162: 156-159.
13. Tanabe O, Akira S, Kaniya T, et al: Genomic structure of the murine IL-6 gene: high degree conservation of potential regulatory sequences between mouse and human. J Immunol 1988; 141: 3875-3881.
14. Torisu M, Katano M, Kimura Y, et al: New approach to management of malignant ascites with a streptococcal preparation, OK-432. Improvement of host immunity and prolongation of survival. Surgery 1983; 93: 357-364.
15. Katano M, Yamamoto H, Kubota E, et al: The possible use of spleen cells for the adoptive immunotherapy of cancer patients. Surg Today 1993; 23: 13-20.
16. Yamagishi H, Ueda Y, Oka T: A case report of immunotherapy on a patient with advanced gastric cancer by adoptive transfer of OK-432-reactive HLA-matched allogeneic lymphocytes. Cancer Immunol Immunother 1998; 46: 113-119.
17. Kirkwood JM, Wilson J, Whiteside TL, et al: Phase 1B trial of picibanil (OK-432) as an immunomodulator in patients with resected high-risk melanoma. Cancer Immunol Immunother 1997; 44: 137-149.
18. D'Andrea A, Rengaraju M, Valiante NM, et al: Production of natural killer cell stimulator factor (interleukin 12) by peripheral blood mononuclear cells. J Exp Med 1992; 176: 1387-1398.
19. Wysocka M, Kubin M, Vieira LQ, et al: Interleukin-12 is required for interferon-γ production and lethality in lipopolysaccharide-induced shock in mice. Eur J Immunol 1995; 25: 672-676.
20. Trinchieri G: Interleukin-12: a cytokine produced by antigen-presenting cell with immunoregulatory functions in the generation of T-helper cells type 1 and cytotoxic lymphocytes. Blood 1994; 84: 4008-4027.
21. Gately MK, Warrier RR, Honasoge S, et al: Administration of recombinant IL-12 to normal mice enhances cytolytic lymphocyte activity and induces production on IFN-γ in vivo. Int Immunol 1994; 6: 157-167.
22. Bohn E, Autenrieth IB: IL-12 is essential for resistance against Yersinia entero-colitica by triggering IFN-γ production in NK cells and CD4+ T cells. J Immunol 1996; 156: 1458-1468.
23. Chan SH, Perussia B, Gupta JW, et al: Induction of interferon gamma production by natural killer cell stimulatory factor: characterization of the responder cells and synergy with other inducers. J Exp Med 1991; 173: 869-879.
24. Heinzel FP, Rerko PM, Ling P, et al: Interleukin-12 is produced in vivo during endotoxemia and stimulates synthesis of gamma-interferon. Infect Immun 1994; 62: 4244-4249.
25. Magram J, Connaughton SE, Warrier RR, et al: IL-12 deficient mice are defective in IFN gamma production and type 1 cytokine responses. Immunity 1996; 4: 471-481.
26. Brunda MJ, Luistro L, Warrier RR, et al: Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J Exp Med 1993; 178: 1223-1230.
27. Tannenbaum CS, Wicker N, Armstrong D, et al: Cytokine and chemokine expression in tumors of mice receiving systemic therapy with IL-12. J Immunol 1996; 156: 693-699.
28. Fujimoto T, Duda RB, Szilvasi A, et al: Streptococcal preparation OK-432 is a potent inducer of IL-12 and a T helper cell 1 dominant state. J Immunol 1997; 158: 5619-5626.
29. Flesch IEA, Hess JH, Huang S, et al: Early interleukin 12 production by macrophages in response to mycobacterial infection depends on interferon-γ and tumor necrosis factor-α. J Exp Med 1995; 181: 1615-1621.
30. Ma X, D'Andrea A, Kubin M, et al: Production of interleukin-12. Res Immunol 1995; 146: 432-438.
31. Tripp CS, Wolf SF, Unanue ER: Interleukin 12 and tumor necrosis factor a are costimulators of interferon γ production by natural killer cells in severe combined immunodeficiency mice with listeriosis, and interleukin 10 is a physiologic antagonist. Proc Natl Acad Sci USA 1993; 90: 3725.
32. Yamamoto N, Zou JP, Li XF, et al: Regulatory mechanisms for production of IFN-γ and TNF by antitumor T cells or macrophages in the tumor-bearing state. J Immunol 1995; 154: 2281-2290.
33. Barth RJ, Jr, Mule JJ, Spiess PJ, Rosenberg SA: Interferon gamma and tumor necrosis factor have a role in tumor regressions mediated by murine CD8+ tumor-infiltrating lymphocytes. J Exp Med 1991; 173: 647-658.
34. Brunda MJ, Sulich V, Bellantoni D: The anti-tumor effect of recombinant interferon alpha and gamma is influenced by tumor location. Int J Cancer 1987; 40: 807-810.
35. Maciejewski J, Selleri C, Anderson S, et al: Fas antigen expression on CD34+ human marrow cells is induced by interferon gamma and tumor necrosis factor alpha and potentiates cytokine-mediated hematopoietic suppression in vitro. Blood 1995; 85: 3183-3190.